March 3, 2026Open Access

Early intravenous immunoglobulin use improves live birth outcomes in women with recurrent pregnancy loss: a propensity score–matched cohort study

Key Points

Live birth rates significantly increased among women receiving intravenous immunoglobulin, particularly at doses below 20 g/d.
Women who started IVIG treatment between 6-12 weeks of gestation showed the most pronounced improvement in outcomes.
This observational analysis involved propensity score matching to strengthen the validity of findings regarding treatment effectiveness.
Findings suggest that intravenous immunoglobulin could enhance pregnancy outcomes in specific cases of recurrent pregnancy loss.

Abstract

IVIG use during pregnancy was associated with a significantly higher LBR among RPL women, particularly when initiated between 6-12 weeks of gestation and administered at a dose <20 g/d; these associations remained robust after excluding cases with abnormal karyotypes. These findings suggest that IVIG may be an effective immunological intervention for improving pregnancy outcomes in selected RPL patients.

Bookmark

View Full Paper

Cite This Study

Xin et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75c10c6e9836116a247a7 https://doi.org/https://doi.org/10.3389/fimmu.2026.1689166

Bookmark

View Full Paper